$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000109355714000137 Filed on May 01, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$47.10M	$29.60M
YoY Change	59.12%	47.26%
Cost Of Revenue	$17.30M	$13.10M
YoY Change	32.06%	22.43%
Gross Profit	$29.80M	$16.50M
YoY Change	80.61%	75.53%
Gross Profit Margin	63.27%	55.74%
Selling, General & Admin	$27.60M	$18.10M
YoY Change	52.49%	17.53%
% of Gross Profit	92.62%	109.7%
Research & Development	$14.50M	$9.300M
YoY Change	55.91%	-1.06%
% of Gross Profit	48.66%	56.36%
Depreciation & Amortization	$1.900M	$1.800M
YoY Change	5.56%	50.0%
% of Gross Profit	6.38%	10.91%
Operating Expenses	$42.10M	$27.40M
YoY Change	53.65%	10.48%
Operating Profit	-$12.30M	-$10.90M
YoY Change	12.84%	-29.22%
Interest Expense	$200.0K	$200.0K
YoY Change	0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.50M	-$11.10M
YoY Change	12.61%	-27.92%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.50M	-$11.10M
YoY Change	12.61%	-21.28%
Net Earnings / Revenue	-26.54%	-37.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$170.5K	-$159.0K
COMMON SHARES
Basic Shares Outstanding	73.30M shares	69.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$57.40M	$45.30M
YoY Change	26.71%	-35.47%
Cash & Equivalents	$45.70M	$18.90M
Short-Term Investments	$11.70M	$26.40M
Other Short-Term Assets	$3.500M	$2.200M
YoY Change	59.09%	4.76%
Inventory	$8.900M	$7.500M
Prepaid Expenses
Receivables	$23.80M	$16.30M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$93.60M	$71.30M
YoY Change	31.28%	-23.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.90M	$18.30M
YoY Change	25.14%	12.96%
Goodwill	$3.200M	$3.200M
YoY Change	0.0%
Intangibles	$3.400M	$4.000M
YoY Change	-15.0%
Long-Term Investments
YoY Change
Other Assets	$800.0K	$1.000M
YoY Change	-20.0%	-16.67%
Total Long-Term Assets	$31.30M	$27.50M
YoY Change	13.82%	9.13%
TOTAL ASSETS
Total Short-Term Assets	$93.60M	$71.30M
Total Long-Term Assets	$31.30M	$27.50M
Total Assets	$124.9M	$98.80M
YoY Change	26.42%	-16.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.800M	$2.200M
YoY Change	118.18%	10.0%
Accrued Expenses	$22.10M	$12.50M
YoY Change	76.8%	1.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.200M	$700.0K
YoY Change	214.29%
Total Short-Term Liabilities	$29.70M	$16.20M
YoY Change	83.33%	0.62%
LONG-TERM LIABILITIES
Long-Term Debt	$4.100M	$6.300M
YoY Change	-34.92%
Other Long-Term Liabilities	$1.100M	$2.700M
YoY Change	-59.26%	17.39%
Total Long-Term Liabilities	$1.100M	$2.700M
YoY Change	-59.26%	17.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.70M	$16.20M
Total Long-Term Liabilities	$1.100M	$2.700M
Total Liabilities	$34.90M	$25.20M
YoY Change	38.49%	36.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$487.9M	-$456.7M
YoY Change	6.83%
Common Stock	$577.9M	$530.3M
YoY Change	8.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$90.00M	$73.60M
YoY Change
Total Liabilities & Shareholders Equity	$124.9M	$98.80M
YoY Change	26.42%	-16.27%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$12.50M	-$11.10M
YoY Change	12.61%	-21.28%
Depreciation, Depletion And Amortization	$1.900M	$1.800M
YoY Change	5.56%	50.0%
Cash From Operating Activities	-$2.400M	-$4.500M
YoY Change	-46.67%	-55.88%
INVESTING ACTIVITIES
Capital Expenditures	$3.900M	$1.400M
YoY Change	178.57%	-39.13%
Acquisitions
YoY Change
Other Investing Activities	-$400.0K	$14.00M
YoY Change	-102.86%	0.0%
Cash From Investing Activities	-$4.300M	$12.60M
YoY Change	-134.13%	7.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$9.700M	$2.700M
YoY Change	259.26%	145.45%
Debt Paid & Issued, Net	$500.0K	$0.00
YoY Change
Cash From Financing Activities	$9.200M	$2.700M
YoY Change	240.74%	145.45%
NET CHANGE
Cash From Operating Activities	-$2.400M	-$4.500M
Cash From Investing Activities	-$4.300M	$12.60M
Cash From Financing Activities	$9.200M	$2.700M
Net Change In Cash	$2.500M	$10.80M
YoY Change	-76.85%	315.38%
FREE CASH FLOW
Cash From Operating Activities	-$2.400M	-$4.500M
Capital Expenditures	$3.900M	$1.400M
Free Cash Flow	-$6.300M	-$5.900M
YoY Change	6.78%	-52.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	14100000	USD
CY2014Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	15900000	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4200000	USD
CY2014Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4800000	USD
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	559500000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	577900000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5000000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8700000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100000	USD
CY2013Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9500000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11000000	shares
CY2013Q4	us-gaap	Assets Assets	122500000	USD
CY2014Q1	us-gaap	Assets Assets	124900000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	93100000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	93600000	USD
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11700000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11400000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11400000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11700000	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2014Q1	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
CY2012Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2200000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43200000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45700000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8100000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18900000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10800000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2500000	USD
CY2014Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	57400000	USD
CY2013Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28700000	USD
CY2014Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	24400000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75100000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72800000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72500000	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74800000	shares
CY2013Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2014Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11100000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12500000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	16900000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12400000	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	17300000	USD
CY2013Q1	us-gaap	Cost Of Revenue CostOfRevenue	13100000	USD
CY2012Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-11-01
CY2014Q1	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	15000000	USD
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2013	us-gaap	Debt Issuance Costs DebtIssuanceCosts	1100000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	700000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	600000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1900000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1800000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11000000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15100000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	140000000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	2200000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1200000	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	300000	USD
CY2013Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2000000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1700000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	5400000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4200000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	3200000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	29800000	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	16500000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-500000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-100000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2200000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3200000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-100000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1100000	USD
CY2014Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4000000	USD
CY2013Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2000000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-200000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	100000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	0	USD
CY2014Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-100000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	100000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3400000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3600000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	200000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	200000	USD
CY2014Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3500000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3900000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	8900000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	9000000	USD
CY2014Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4500000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4800000	USD
CY2014Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	900000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	300000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	38400000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	34900000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122500000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124900000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	29700000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32100000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	6300000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1700000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2300000	USD
CY2014Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2300000	USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (“CGM”) systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2700000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9200000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4300000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12600000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4500000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2400000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-12500000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-11100000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3500000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	27400000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10900000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	42100000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12300000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7600000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2100000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2600000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2900000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2013Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	800000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4800000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4400000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	900000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	800000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1100000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1700000	USD
CY2014Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	100000	USD
CY2013Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2014Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3000000	USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4900000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1400000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3900000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3400000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9700000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2700000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	18900000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2600000	USD
CY2013Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	600000	USD
CY2014Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1100000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22900000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20700000	USD
CY2014Q1	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	21500000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	500000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9300000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14500000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-487900000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-475400000	USD
CY2014Q1	us-gaap	Revenues Revenues	47100000	USD
CY2013Q1	us-gaap	Revenues Revenues	29600000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	46700000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	27800000	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2200000	USD
CY2014Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	2200000	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	4600000	USD
CY2014Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	4100000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27600000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18100000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8700000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5000000	USD
CY2013Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	900000	USD
CY2012Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2013Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	200000	USD
CY2014Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	800000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84100000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	90000000	USD
CY2014Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	500000	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical trial expenses, allowance for bad debt, accounting for the SweetSpot acquisition including contingent consideration, and share-based compensation expense. </font></div></div>
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73300000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69800000	shares
CY2013Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	26100000	USD
CY2014Q1	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	23800000	USD
CY2014Q1	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1100000	USD
CY2013Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1200000	USD
CY2014Q1	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	5400000	USD
CY2013Q4	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	3600000	USD
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement BusinessAcquisitionContingentConsiderationSettlement	1100000	USD
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement Shares Issued BusinessAcquisitionContingentConsiderationSettlementSharesIssued	89296	shares
CY2014Q1	dxcm	Business Acquisition Equity Interests Issued Or Issuable Additional Number Of Shares Issuable BusinessAcquisitionEquityInterestsIssuedOrIssuableAdditionalNumberOfSharesIssuable	267880	shares
CY2012Q1	dxcm	Business Combination Contingent Consideration Liability Shares BusinessCombinationContingentConsiderationLiabilityShares	357176	shares
CY2013Q4	dxcm	Clinical Trials ClinicalTrials	300000	USD
CY2014Q1	dxcm	Clinical Trials ClinicalTrials	200000	USD
CY2013Q4	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	4200000	USD
CY2014Q1	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	5400000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2014Q1	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	400000	USD
CY2013Q1	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	700000	USD
CY2013Q1	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	1800000	USD
CY2014Q1	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	400000	USD
CY2014Q1	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	1200000	USD
CY2013Q1	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	300000	USD
CY2012Q4	dxcm	Line Of Credit Facility Borrowing Base Percentage Of Eligible Accounts LineOfCreditFacilityBorrowingBasePercentageOfEligibleAccounts	0.80
CY2014Q1	dxcm	Option To Renew Lease OptionToRenewLease	P5Y
CY2014Q1	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.040
CY2014Q1	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2012Q4	dxcm	Prime Rate Plus PrimeRatePlus	0.005
CY2014Q1	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2014Q1	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	500000	USD
CY2013	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	500000	USD
CY2013Q3	dxcm	Researchand Development Arrangement Valueof Grant ResearchandDevelopmentArrangementValueofGrant	4000000	USD
CY2014Q1	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2013Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	500000	USD
CY2014Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	1000000	USD
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
CY2014Q1	dxcm	Term Of Lease TermOfLease	P3Y
CY2014Q1	dxcm	Working Capital WorkingCapital	63900000	USD
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74917857	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
CY2014Q1	dei	Trading Symbol TradingSymbol	DXCM

Files In Submission

Name	View Source	Status
0001093557-14-000137-index-headers.html	Edgar Link	pending
0001093557-14-000137-index.html	Edgar Link	pending
0001093557-14-000137.txt	Edgar Link	pending
0001093557-14-000137-xbrl.zip	Edgar Link	pending
dxcm-03312014x10q.htm	Edgar Link	pending
dxcm-20140331.xml	Edgar Link	completed
dxcm-20140331.xsd	Edgar Link	pending
dxcm-20140331_cal.xml	Edgar Link	unprocessable
dxcm-20140331_def.xml	Edgar Link	unprocessable
dxcm-20140331_lab.xml	Edgar Link	unprocessable
dxcm-20140331_pre.xml	Edgar Link	unprocessable
dxcm03312014ex1030.htm	Edgar Link	pending
dxcm03312014ex3101.htm	Edgar Link	pending
dxcm03312014ex3102.htm	Edgar Link	pending
dxcm03312014ex3201.htm	Edgar Link	pending
dxcm03312014ex3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2014 Q1 Form 10-Q Financial Statement

#000109355714000137 Filed on May 01, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2014 Q1 Form 10-Q Financial Statement

#000109355714000137 Filed on May 01, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm